Actiq DC

An oral/transmucosal-“lollipop” delivery system developed to alleviate breakthrough pain in cancer patients. It is also prescribed for off-label indications, including bone injuries, migraines, back pain, cluster headaches, neuropathy, arthritis, and other moderate to severe chronic, non-malignant pain.

The Actiq lollipop is available in 6 different dosage strengths and is indicated for management of breakthrough cancer pain in patients with malignancies who are already receiving opiates for pain control.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.